Search Results
Search here to find what you are looking for. If you are searching for a Teva product, you may want to try searching in one of our product catalogues or feel free to contact us for assistance.
Showing 10 from 25 results
Toronto, Ontario (February 7, 2024) - Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., is proud to announce that it has been named to Forbes list of Canada’s Best Employers 2024. Teva Canada ranked No. 1 of Drugs & Biotechnology employers and No. 28 of 300 overall employers.
Teva Canada announces new General Manager, Michael Sine
I have had the pleasure of collaborating with Christine for many years and wish her the best as she moves on to new experiences.
Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, join a growing list of provinces providing public drug plan reimbursement for Teva Canada’s AJOVY® (fremanezumab), for the preventive treatment of migraine in adults
Public formulary and program coverage makes AJOVY® accessible
to more migraine patients across Canada
Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, join a growing list of provinces providing public drug plan reimbursement for Teva Canada’s AJOVY® (fremanezumab), for the preventive treatment of migraine in adults
Public formulary and program coverage makes AJOVY® accessible
to more migraine patients across Canada
New public drug plan reimbursement for AJOVY®
Teva Canada Welcomes Public Drug Plan Reimbursement by Alberta, Saskatchewan, Québec, Veteran Affairs Canada and the Non-Insured Health Benefits Program for patients prescribed AJOVY® (fremanezumab) for the Preventive Treatment of Migraine in Adults
Important Information – Voluntary Nationwide Recall
Novo-Gesic Forte® 500 mg (Acetaminophen) Tablets (DIN 00482323)
Teva Canada Provides New Patient Resource to Empower Those Living with Chronic Conditions
Life Effects™ website features real-life stories from patients and caregivers about the reality of living with one or more chronic conditions